CN104755933B - 用于鉴定hiv中和抗体的方法 - Google Patents

用于鉴定hiv中和抗体的方法 Download PDF

Info

Publication number
CN104755933B
CN104755933B CN201380052377.5A CN201380052377A CN104755933B CN 104755933 B CN104755933 B CN 104755933B CN 201380052377 A CN201380052377 A CN 201380052377A CN 104755933 B CN104755933 B CN 104755933B
Authority
CN
China
Prior art keywords
antibody
cells
binding
hiv
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380052377.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755933A (zh
Inventor
朱利安·米格尔·布兰科阿韦斯
约根·卡里洛莫利纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida, Laboratorios del Dr Esteve SA filed Critical IrsiCaixa Institut de Recerca de la Sida
Publication of CN104755933A publication Critical patent/CN104755933A/zh
Application granted granted Critical
Publication of CN104755933B publication Critical patent/CN104755933B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
CN201380052377.5A 2012-09-06 2013-09-06 用于鉴定hiv中和抗体的方法 Expired - Fee Related CN104755933B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382342.9A EP2706356A1 (en) 2012-09-06 2012-09-06 Methods for identifying HIV neutralizing antibodies
EP12382342.9 2012-09-06
PCT/EP2013/068446 WO2014037490A1 (en) 2012-09-06 2013-09-06 Methods for identifying hiv neutralizing antibodies

Publications (2)

Publication Number Publication Date
CN104755933A CN104755933A (zh) 2015-07-01
CN104755933B true CN104755933B (zh) 2017-06-09

Family

ID=46829683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380052377.5A Expired - Fee Related CN104755933B (zh) 2012-09-06 2013-09-06 用于鉴定hiv中和抗体的方法

Country Status (16)

Country Link
US (1) US9952218B2 (enExample)
EP (2) EP2706356A1 (enExample)
JP (1) JP6282655B2 (enExample)
KR (1) KR20150081255A (enExample)
CN (1) CN104755933B (enExample)
AU (1) AU2013311626A1 (enExample)
BR (1) BR112015004970A2 (enExample)
CA (1) CA2884165A1 (enExample)
ES (1) ES2643268T3 (enExample)
IL (1) IL237613A0 (enExample)
IN (1) IN2015DN02730A (enExample)
MX (1) MX2015003047A (enExample)
PT (1) PT2893349T (enExample)
RU (1) RU2015112297A (enExample)
WO (1) WO2014037490A1 (enExample)
ZA (1) ZA201502210B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166313B (zh) * 2016-07-01 2018-09-07 浙江大学 一种艾滋病孕妇血液净化器
CN106075626B (zh) * 2016-07-01 2018-06-26 浙江大学 一种艾滋病血液净化治疗仪

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
CN1668633A (zh) * 2002-07-23 2005-09-14 杜克大学 IgG Fc/HIV－gp120/C3d 融合蛋白质
WO2005121175A2 (en) * 2004-06-08 2005-12-22 Novartis Vaccines And Diagnostics Inc. Env polypeptide complexes and methods of use
US20070243208A1 (en) * 1999-03-16 2007-10-18 The Govt. Of The U.S.A As Represented By The Secretary Of The Dept. Of Health & Human Services Novel chimeric protein for prevention and treatment of hiv infection
CN101146827A (zh) * 2005-02-03 2008-03-19 诺华疫苗和诊断公司 Hiv tat-cd4杂合分子及其使用方法
CN101551392A (zh) * 2008-01-22 2009-10-07 厦门大学 一种检测人乳头瘤病毒中和抗体的方法
CN101846679A (zh) * 2009-03-25 2010-09-29 邢安辉 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US8911728B2 (en) * 2010-05-21 2014-12-16 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070243208A1 (en) * 1999-03-16 2007-10-18 The Govt. Of The U.S.A As Represented By The Secretary Of The Dept. Of Health & Human Services Novel chimeric protein for prevention and treatment of hiv infection
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
CN1668633A (zh) * 2002-07-23 2005-09-14 杜克大学 IgG Fc/HIV－gp120/C3d 融合蛋白质
WO2005121175A2 (en) * 2004-06-08 2005-12-22 Novartis Vaccines And Diagnostics Inc. Env polypeptide complexes and methods of use
CN101146827A (zh) * 2005-02-03 2008-03-19 诺华疫苗和诊断公司 Hiv tat-cd4杂合分子及其使用方法
CN101551392A (zh) * 2008-01-22 2009-10-07 厦门大学 一种检测人乳头瘤病毒中和抗体的方法
CN101846679A (zh) * 2009-03-25 2010-09-29 邢安辉 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bifunctional fusion proteins of the human enguneered antibody domain m36 with human solbule CD4 are potent inhibitors of diverse HIV-1 isolates;Chen W et al;《Antiviral Research》;20101001;第88卷(第1期);107-115 *

Also Published As

Publication number Publication date
EP2893349A1 (en) 2015-07-15
ES2643268T3 (es) 2017-11-21
KR20150081255A (ko) 2015-07-13
RU2015112297A (ru) 2016-10-27
US9952218B2 (en) 2018-04-24
US20150233924A1 (en) 2015-08-20
CA2884165A1 (en) 2014-03-13
IN2015DN02730A (enExample) 2015-09-04
IL237613A0 (en) 2015-04-30
AU2013311626A1 (en) 2015-04-30
EP2706356A1 (en) 2014-03-12
MX2015003047A (es) 2015-07-14
ZA201502210B (en) 2016-11-30
JP6282655B2 (ja) 2018-02-21
JP2015530575A (ja) 2015-10-15
HK1211694A1 (en) 2016-05-27
BR112015004970A2 (pt) 2017-07-04
EP2893349B1 (en) 2017-08-16
PT2893349T (pt) 2018-04-12
WO2014037490A1 (en) 2014-03-13
CN104755933A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
Graham et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B. 1.1. 7 variant
Ou et al. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion
Alam et al. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
Liao et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
Parrish et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7
Fouda et al. HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies
Perez et al. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41
Bego et al. Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells
Williams et al. Identification of HIV gp41-specific antibodies that mediate killing of infected cells
Wang et al. Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro
Hong et al. Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120
Maciola et al. Neutralizing antibody responses to SARS-CoV-2 in recovered COVID-19 patients are variable and correlate with disease severity and receptor-binding domain recognition
Lertjuthaporn et al. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7
Lai et al. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41
Ringe et al. Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity
US20250296985A1 (en) Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19)
Rossignol et al. Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells
Armani-Tourret et al. Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis
US9952218B2 (en) Methods for identifying HIV neutralizing antibodies
Mathew et al. Display of the HIV envelope protein at the yeast cell surface for immunogen development
CN114316062B (zh) 靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
Carrillo et al. Gp120/CD4 blocking antibodies are frequently elicited in ART-naive chronically HIV-1 infected individuals
Ferraz et al. High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor
HK1211694B (en) Methods for identifying hiv neutralizing antibodies
Eslahpazir et al. Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180727

Address after: Badalona, Spain

Patentee after: Fundacio Privada Institut de Recerca de La Sida-Caixa

Address before: Barcelona

Co-patentee before: Fundacio Privada Institut de Recerca de La Sida-Caixa

Patentee before: Esteve Labor Dr.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170609

Termination date: 20180906

CF01 Termination of patent right due to non-payment of annual fee